Table 6.

Univariate probabilities comparing subjects who relapsed prior to transplant to subjects who never relapsed. All subjects received an autologous transplant for rhabdomyosarcoma between 1989 and 2003, reported to the CIBMTR.

	No relapse prior to tx		Relapsed prior to tx
Outcome of interest	N (eval)	Probability (95% CI)	N(eval)	Probability (95% CI)	P-valuec
Treatment related mortalitya	38		21
@ 1 year		5 (1–15)%		--	N/A
@ 3 years		5 (1–15)%		--	N/A
@ 5 years		5 (1–15)%		--	N/A
Progression/relapsea	38		21
@ 1 year		54 (38–70) %		74 (52–90)%	0.135
@ 3 years		63 (47–77) %		74 (52–90)%	0.400
@ 5 years		63 (47–77) %		74 (52–90)%	0.400
Progression free survivalb	38		21
@ 1 year		41 (26–57) %		26 (10–48) %	0.275
@ 3 years		32 (18–48) %		26 (10–48) %	0.664
@ 5 years		32 (18–48) %		26 (10–48) %	0.664
Overall survivalb	38		21
@ 1 year		53 (37–68) %		62 (41–81) %	0.487
@ 3 years		39 (25–55) %		43 (23–64) %	0.800
@ 5 years		36 (22–52) %		29 (12–49) %	0.532

^aProbabilities of relapse, treatment-related mortality, platelet & neutrophil engraftment were calculated using the cumulative incidence function

^bProbabilities of overall survival and progression free survival were calculated using the Kaplan-Meier product limit estimate.

^cPointwise P-value